Dimensional Fund Advisors LP Has $87.88 Million Stock Holdings in GSK plc (NYSE:GSK)

Dimensional Fund Advisors LP lifted its stake in GSK plc (NYSE:GSK) by 0.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,598,570 shares of the pharmaceutical company’s stock after purchasing an additional 18,492 shares during the quarter. Dimensional Fund Advisors LP’s holdings in GSK were worth $87,884,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of GSK. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after buying an additional 278 shares during the period. GC Wealth Management RIA LLC boosted its stake in GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares during the period. Jacobi Capital Management LLC grew its position in GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after purchasing an additional 389 shares in the last quarter. Gladstone Institutional Advisory LLC raised its stake in GSK by 3.4% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock valued at $413,000 after purchasing an additional 407 shares during the period. Finally, CENTRAL TRUST Co lifted its holdings in shares of GSK by 5.6% in the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock valued at $262,000 after purchasing an additional 414 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the subject of several research analyst reports. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price for the company. Eight equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.58.

GSK Stock Up 2.8 %

GSK stock opened at $39.13 on Wednesday. The firm has a market cap of $80.73 billion, a PE ratio of 24.61, a PEG ratio of 1.12 and a beta of 0.56. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a fifty day simple moving average of $37.57 and a 200 day simple moving average of $36.02. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a $0.3932 dividend. The ex-dividend date was Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.02%. GSK’s payout ratio is presently 100.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.